Trial Profile
Efficacy and tolerability of switching to telmisartan/amlodipine in patients with uncontrolled hypertension on RAS inhibitor monotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 May 2012
Price :
$35
*
At a glance
- Drugs Amlodipine/telmisartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms TEAMSTA Switch
- Sponsors Boehringer Ingelheim
- 01 May 2012 New trial record
- 29 Apr 2012 Results presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension (ESH), according to a Boehringer Ingelheim media release.
- 29 Apr 2012 Results published in a Boehringer Ingelheim media release.